Medicare Enrolled
Dr. Jay Rhee, M.D.
Hematology & Oncology · Atlanta, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rhee from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rhee?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rhee
Dr. Jay Rhee is a hematology & oncology specialist in Atlanta, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Rhee performed 34,560 Medicare services across 1,910 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rhee received a total of $6,748 from 69 pharmaceutical and/or device companies across 330 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rhee is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 14% volume in GA
$6,748 industry payments
Medicare Practice Summary
Medicare Utilization ↗34,560
Medicare services
Top 14% in GA for hematology & oncology
1,910
Unique beneficiaries
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,728 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 10,140 | $17 | $44 |
| Pembrolizumab injection (Keytruda) | 9,800 | $41 | $110 |
| Iron infusion (Monoferric) | 6,200 | $15 | $65 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,169 | $8 | $27 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,122 | $0 | $0 |
| Injection, fulvestrant, 25 mg | 780 | $7 | $80 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
730 | $5 | $25 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
670 | $91 | $260 |
| Anti-nausea injection (Aloxi/palonosetron) | 640 | $1 | $5 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
409 | $59 | $168 |
| Injection, leucovorin calcium, per 50 mg | 345 | $3 | $9 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
345 | $2 | $5 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
310 | $11 | $60 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
231 | $100 | $525 |
| Injection, granisetron hydrochloride, 100 mcg | 230 | $0 | $1 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
176 | $12 | $82 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
168 | $22 | $118 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
107 | $22 | $131 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
104 | $48 | $235 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
95 | $26 | $126 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
78 | $1 | $6 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
70 | $55 | $260 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
68 | $1 | $2 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
63 | $50 | $250 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
56 | $126 | $376 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
51 | $115 | $429 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
49 | $15 | $90 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
45 | $62 | $250 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
38 | $10 | $97 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
35 | $2 | $5 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
34 | $171 | $550 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
28 | $24 | $194 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
27 | $43 | $218 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 24 | $313 | $1,325 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
24 | $1 | $3 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
23 | $133 | $475 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
21 | $3 | $15 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
19 | $15 | $70 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
19 | $60 | $172 |
| New patient office visit, complex (60-74 min) | 17 | $168 | $544 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
20.0% high complexity
72.7% medium
7.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,748
Total received (2018-2024)
Avg $964/year across 7 years
Top 40% in GA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
330
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,492 (96.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$256 (3.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,338
2023
$994
2022
$719
2021
$1,236
2020
$353
2019
$1,110
2018
$998
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$260
AstraZeneca Pharmaceuticals LP
$119
Merck Sharp & Dohme LLC
$114
GlaxoSmithKline, LLC.
$91
Daiichi Sankyo Inc.
$86
ABBVIE INC.
$82
Regeneron Healthcare Solutions, Inc.
$79
Gilead Sciences, Inc.
$65
Takeda Pharmaceuticals U.S.A., Inc.
$46
Eisai Inc.
$43
Novartis Pharmaceuticals Corporation
$43
Incyte Corporation
$42
ADC Therapeutics America, Inc.
$39
TerSera Therapeutics LLC
$27
GENZYME CORPORATION
$24
BeiGene USA, Inc.
$23
Exelixis Inc.
$22
Karyopharm Therapeutics Inc.
$20
Genentech USA, Inc.
$20
Agios Pharmaceuticals, Inc.
$18
Spectrum Pharmaceuticals Inc.
$18
Alexion Pharmaceuticals, Inc.
$17
Bayer Healthcare Pharmaceuticals Inc.
$16
RECORDATI_RARE_DISEASES_INC.
$15
ARRAY BIOPHARMA INC
$8
Top 3 companies account for 36.8% of 2024 payments
All-time payments by company (2018-2024) ›
Stryker Corporation
$519
PFIZER INC.
$496
AstraZeneca Pharmaceuticals LP
$381
Novartis Pharmaceuticals Corporation
$349
Amgen Inc.
$318
Seagen Inc.
$298
Genentech USA, Inc.
$242
GENZYME CORPORATION
$214
Merck Sharp & Dohme LLC
$212
E.R. Squibb & Sons, L.L.C.
$201
Pharmacyclics LLC, An AbbVie Company
$183
Daiichi Sankyo Inc.
$164
Gilead Sciences, Inc.
$157
Janssen Biotech, Inc.
$157
Smith+Nephew, Inc.
$149
ASD Specialty Healthcare, LLC
$140
Regeneron Healthcare Solutions, Inc.
$137
Incyte Corporation
$134
ABBVIE INC.
$133
Ethicon US, LLC
$114
Janssen Pharmaceuticals, Inc
$112
Eisai Inc.
$97
GlaxoSmithKline, LLC.
$91
Takeda Pharmaceuticals U.S.A., Inc.
$91
Exelixis Inc.
$89
Seattle Genetics, Inc.
$88
Epizyme, Inc.,
$85
Alexion Pharmaceuticals, Inc.
$77
Astellas Pharma US Inc
$76
Celgene Corporation
$73
AbbVie, Inc.
$72
Lilly USA, LLC
$71
BeiGene USA, Inc.
$63
Rigel Pharmaceuticals, Inc.
$61
Merck Sharp & Dohme Corporation
$60
ADC Therapeutics America, Inc.
$58
Kite Pharma, Inc.
$57
Bayer HealthCare Pharmaceuticals Inc.
$54
Pharmacyclics LLC, an AbbVie Company
$46
EISAI INC.
$41
Mirati Therapeutics, Inc.
$40
Boehringer Ingelheim Pharmaceuticals, Inc.
$40
Agios Pharmaceuticals, Inc.
$36
Karyopharm Therapeutics Inc.
$32
TerSera Therapeutics LLC
$27
Lexicon Pharmaceuticals, Inc.
$26
ARRAY BIOPHARMA INC
$26
AbbVie Inc.
$23
TESARO, Inc.
$22
Biocompatibles, Inc.
$22
Shire North American Group Inc
$21
Dova Pharmaceuticals
$19
Spectrum Pharmaceuticals Inc.
$18
Helsinn Therapeutics (U.S.), Inc.
$18
Dendreon Pharmaceuticals LLC
$17
JAZZ PHARMACEUTICALS INC.
$17
Puma Biotechnology, Inc.
$16
Verastem, Inc.
$16
Bayer Healthcare Pharmaceuticals Inc.
$16
SERVIER PHARMACEUTICALS LLC
$15
RECORDATI_RARE_DISEASES_INC.
$15
Secura Bio, Inc.
$15
PORTOLA PHARMACEUTICALS, INC.
$15
Epizyme, Inc.
$15
Novo Nordisk Inc
$14
Ipsen Biopharmaceuticals, Inc
$13
CTI BioPharma Corp.
$13
Octapharma USA, Inc.
$12
Sirtex Medical Inc
$10
Top 3 companies account for 20.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ANDEXXA · Abraxane · Alecensa · Aliqopa · Andexxa · Avastin · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · CABLIVI · CABOMETYX · CALQUENCE · CHANTIX · CREON · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · Doptelet · ECHELON FLEX Stapler · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · EVEREST SPINAL SYSTEM · Enhertu · Erleada · FARYDAK · FASLODEX · FRUZAQLA · GAZYVA · GILOTRIF · GRAFIX · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lupron · MEKINIST · MONJUVI · NINLARO · Nerlynx · Neulasta · NovoSeven RT · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OXBRYTA · PADCEV · PANZYGA · PIQRAY · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Phesgo · ROLVEDON · RYDAPT · Revlimid · Rezlidhia · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · STRAVIX · SYLVANT · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · THERASPHERE - BIO · TUKYSA · Tavalisse · Tazverik · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · Venclexta · Vonjo · WELIREG · XARELTO · XPOVIO · Xermelo · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
178
Per 100K population
16.7
County median income
$91,490
Nearest hospital
PIEDMONT HOSPITAL, INC
3.6 mi
3.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rhee is a mixed practice specialist, with above-average Medicare volume (top 14% in GA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rhee experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Rhee performed 10,140 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rhee receive payments from pharmaceutical companies?
Yes. Dr. Rhee received a total of $6,748 from 69 companies across 330 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rhee's costs compare to other hematology & oncology specialists in Atlanta?
Dr. Rhee's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rhee) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Atlanta
Browse hematology & oncology specialists in Atlanta ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in GA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in GA
Which GA hematology & oncology specialists receive the most from drug and device companies.
By company
Stryker Corporation Payments to Doctors
See all physicians who received payments from Stryker Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology